Core Insights - Elutia Inc. is launching its EluPro™ Antibiotic-Eluting BioEnvelope for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society's annual meeting in San Diego from April 25-27, 2025 [1][3] - The EluPro product features a proprietary biomatrix that enhances performance and handling, providing a soft and conforming feel compared to synthetic alternatives, while delivering a dual-antibiotic combination for effective bacterial colonization reduction [2][3] Company Overview - Elutia focuses on developing and commercializing drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [5] - The company is positioned to address the growing demand for implantable technologies as the population requiring such devices increases [5]
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes